Allakos Inc.’s $402 Million Common Stock Offering


Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 5,227,272 shares of common stock of Allakos Inc. for total gross proceeds of approximately $402 million.

Based in Redwood City, California, Allakos is a clinical stage biotechnology company developing AK002, their wholly owned monoclonal antibody for the treatment of various eosinophil and mast cell related diseases.

Goldman Sachs & Co. LLC, Jefferies LLC, William Blair & Company, L.L.C. and LifeSci Capital LLC acted as joint book-running managers in the deal.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Jeffrey C. Lau and Stephanie Y. Cheng. Partner Frank J. Azzopardi and associate Michael V. Policastro provided intellectual property and technology advice. Partner Rachel D. Kleinberg provided tax advice.

Involved fees earner: Frank Azzopardi – Davis Polk & Wardwell; Stephanie Cheng – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Jeffrey Lau – Davis Polk & Wardwell; Michael Policastro – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman Sachs & Co.; Jefferies Finance LLC; LifeSci Capital LLC; William Blair & Company, L.L.C.;

Author: Ambrogio Visconti